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Editorial Comment
Unobstructed Thinking (and
Terminology) Is Called for in
the Understanding and
Management of Hypertrophic
Cardiomyopathy*
JOHN MICHAEL CRILEY, MD, FACC
Torrance, California
The ill and unfit choice of words wonderfully obstructs the
understanding.
—Sir Francis Bacon
Don’t just do something, stand there!
—Anon.
Conventional wisdom. Conventional wisdom has accepted
and promoted the primacy of obstruction in the pathophysiol-
ogy of hypertrophic cardiomyopathy. The dynamic intracavi-
tary pressure gradient, universally equated with outflow tract
obstruction, is thought to be the cause of the inordinate
hypertrophy of the left ventricle as well as the physical signs,
symptoms and threat of premature mortality that characterize
this condition. Synonyms, including idiopathic hypertrophic
subaortic stenosis, muscular subaortic stenosis and hypertrophic
obstructive cardiomyopathy, are widely used by physicians in their
professional writings and discussions and in their characteriza-
tions and explanation of the disease to their patients.
If outflow obstruction is the cause, it logically follows that
relief of obstruction should be the cure. A sphincteric contrac-
tion ring in the outflow tract was compellingly described by
early surgical investigators: “forceful contraction of the outflow
tract upon the examining finger is evident during systole” and
“the compression around the finger was nothing short of
painful”; but the presence of this sphincter could not be later
confirmed by cineangiography or echocardiography. When
these imaging techniques became available, they exculpated
the fabled outflow tract sphincter and implicated instead
anterior motion of the mitral valve leaflets (hardly capable of
a painful finger squeeze!) in the presumed obstruction. Mitral
valve replacement was then advocated in lieu of muscle
resection when it was determined that the mitral leaflets, and
not a muscular sphincter, caused the obstruction.
On the basis of observations that myocardial infarctions
could abolish the pressure gradient, procedures have been
devised to obstruct the nutrient arteries supplying the subaor-
tic septum (1). Abolition of the pressure gradient has thus been
the desired and most readily measured end point of all forms
of therapy despite the lack of clear documentation that it has
a favorable impact on the natural history of the disease.
Dual-chamber pacing is yet another arrow in the therapeu-
tic quiver (2). The logic behind this strategy is as follows: In
some patients, acute or chronic reduction or relief of the
pressure gradient occurs with pacing of the right ventricle.
Atrial transport function is preserved by sensing atrial depo-
larization, and preemptive triggering of the ventricle is induced
before native conduction can take place. Attendant with
pressure gradient reduction has been in some instances reduc-
tion in filling pressure, along with improvement in exercise
tolerance and symptoms.
This is not truly “dual-chamber pacing” because only one
chamber, the ventricle is usually paced, but the term is widely
used despite its inexactitude. The terms “P-synchronous pac-
ing” and “DDD pacing” are also used to describe the proce-
dure, which avoids the connotation that both chambers are
being paced. However, “P-synchronous pacing” is misleading
because “synchronous” implies simultaneous action, rather
than the advantageous sequential action of atrial sensing
followed by ventricular pacing that is actually used. “DDD”
obscures the modalities used, namely, “VAT” (ventricular
pacing, atrial sensing, with triggering of the ventricle), or what
might be more clearly described as “atrial triggered ventricular
pacing.”
The proposed mechanism underlying the reduction in int-
racavitary gradient is that pre-excitation of the apex alters the
sequence of contraction of the interventricular septum such
that the left ventricular outflow tract is widened (2). This
concept is similar to a disputed explanation given for the
mechanism of gradient reduction with ventricular myotomy
and myectomy procedures, namely, the production of left
bundle branch block.
The article in this issue of the Journal by Rishi et al. (3)
explores the use of atrial triggered ventricular pacing (VAT
pacing) in a small pediatric cohort of symptomatic patients
with hypertrophic cardiomyopathy. The relevance of this test
of the “obstruction (gradient) causes hypertrophy” hypothesis
is especially pertinent in children because the degree of
hypertrophy can advance rapidly in childhood and adolescence
(2), dooming its victims to a potentially life-threatening dis-
ease. Although 6 of the 10 patients were 13 to 17 years old, and
4 of the 7 “responders” were .13 years old at the inception of
the study, it could still serve as a valuable insight into the
hypothesis. The decrease in pulmonary capillary wedge pres-
sure is reassuring, although the spontaneous variability of this
measurement with volume status and other factors makes it a
less than solid end point when measured at one point in time.
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The modest increases in treadmill exercise time and the
subjective improvement on serial quality of life questionnaires
could be explained by a training effect and a placebo effect,
respectively.
These latter effects can only be validly tested with random-
ized, double-blind, controlled studies of the type recently
reported by Nishimura et al. (4) in 19 adult patients with
hypertrophic cardiomyopathy. Improvement in quality of life
indexes, exercise duration and maximal oxygen consumption in
their sham treatment arm (implanted pacemakers programed
in the AAI mode, with a backup rate of 30 beats/min) suggests
a strong placebo effect of the instrumentation and a training
effect on exercise performance.
Until we have more data, pacing, particularly in children,
should remain experimental, and instances where it is used
should be rigorously followed up and reported. Dual-chamber
generators and electrodes pose special challenges in infants
and small children, including the need for changing electrodes
to match growth and concerns about the functional life expect-
ancy of the devices. Some patients, including one in the current
study, are subjected to radio frequency ablation of the atrio-
ventricular node, rendering the recipient permanently pace-
maker dependent. A thoracotomy for placement of epicardial
leads was used in another patient in the current study, a
procedure that should not be entered into lightly. Pacemakers
also have a potential for causing arrhythmias, either by me-
chanical stimulation of the ventricular endocardium or through
iatrogenic reentry phenomena. The heightened public aware-
ness of the “painful debate” engendered by a Wall Street
Journal article (5) and the emotional letters in response to it
make it imperative that we look before we leap, particularly in
regard to the use of implanted devices in children.
It is of considerable concern that recent attempts to recruit
adult patients for a multicenter, prospective, randomized trial
evaluating sham pacing against atrial triggered ventricular
pacing have reportedly been hampered by a meager enroll-
ment of patients. An explanation given for the lack of referral
is that physicians are already convinced that pacing is a proven
therapeutic modality.
The license provided an editorial comment invitee compels
me to provide some other cautionary comments at this junc-
ture. In its relatively short history since Brock (6) and Teare (7)
first brought the disease into prominence, no other disease in
cardiology has caused more controversy and needs more
reasoned understanding than hypertrophic cardiomyopathy.
At the root of the controversy are the disputes and misunder-
standings regarding the dynamic intracavitary pressure gradi-
ents that underlie the condition’s compelling nosology. These
gradients are properly termed “dynamic” in that they respond
in a manner totally unlike the gradients associated with fixed
lesions such as aortic stenosis. Whether they should be equated
with “outflow tract obstruction” is another matter.
Unconventional wisdom. The opening paragraphs of this
editorial reiterated concepts taught to medical students and
medical trainees because they are implicit in the terminology
and firmly believed by our academic faculties and by the vast
majority of cardiologists. These beliefs survive despite having
been repeatedly challenged with observations that question the
presence and importance of obstruction, as conventionally
defined as a hindrance to ejection, in the pathophysiology of
hypertrophic cardiomyopathy (8). A summary of these chal-
lenges as well as an alternative understanding for dynamic
intracavitary gradients follows:
1. Most patients with hypertrophic cardiomyopathy do not
have pressure gradients either at rest or with provocation.
2. Symptomatic patients with hypertrophic cardiomyopathy
without gradients have a worse prognosis than those who do
have gradients.
3. Ventricles with dynamic gradients have better systolic
function than those that do not. Provocation or enhancement
of a gradient is associated with an increase in the rate and
degree of left ventricular emptying (the antithesis of increased
obstruction, which would hinder the rate of emptying), despite
the presence of systolic anterior movement of the mitral valve.
4. Dynamic pressure gradients occur in normal ventricles
under a variety of perturbations that decrease left ventricular
filling, decrease impedance to left ventricular ejection or
increase the contractile state of the ventricle. Examples include
blood loss, septic shock, pericardial tamponade and dobut-
amine infusion stress echocardiography.
5. Dynamic pressure gradients occur after aortic valve
replacement for aortic stenosis. In a recent study, high intra-
cavitary flow velocity signals were recorded, but systolic ante-
rior motion of the mitral apparatus was noted in only 5 of 41
of these patients (9). One of these five patients had mitral
annulus calcification, and the remaining four were noted to
have elongated and redundant mitral valve architecture. It
might be reasoned that these intracavitary pressure gradients
could be the cause, rather than the result of systolic anterior
movement. The high pressure in the submitral cavity and low
pressure in the outflow tract could be the forces that bend the
elongated leaflet tips and subvalvar apparatus toward the low
pressure zone.
6. The mechanism underlying observations 3 to 5 has been
variously called “cavity obliteration” (8), “cavity squeezing” (9)
and “cavitary elimination” (10), which are clear, unambiguous
descriptive terms. It occurs when there is excessive contractile
force applied to the ventricle beyond that needed for ejection
of the stroke volume; a mismatch between work needed and
work performed. The contents of the entire submitral region of
the ventricle are rapidly eliminated, with the residual “dead
space” largely confined to the minimally contractile outflow
region downstream from the mitral valve (8).
7. High pressures recorded from catheters entrapped in the
myocardium are not responsible for the intracavitary gradients
described in observations 3 to 6. This measurement artifact,
accurately termed “catheter entrapment,” does not result in
Doppler velocities comparable to the pressure differences
noted with cavity obliteration. Accordingly, catheter entrap-
ment should not be equated with cavity obliteration.
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Unobstructed understanding. These observations are not
meant to imply that high pressure in the ventricle, whether it
results from true obstruction or cavity obliteration, is benign;
nor should these remarks be construed to imply that abolition
of a gradient is not beneficial. The observations are being
elucidated for the purpose of better understanding of the
mechanism of nonobstructive dynamic gradients, in the hope
that neither gradients and obstruction, nor cavity obliteration
and catheter entrapment, will continue to be equated. When
the terms are indiscriminately interchanged, it “wonderfully
obstructs the understanding.” Clear and unobstructed thinking
is aided by clarity of terminology.
The stimulus to enumerate these observations is also pred-
icated on the belief that a rush to embrace treatment modal-
ities based on incomplete information or worse, misquoted
information, is not likely to serve our patients well. The claim
that septal pre-excitation widens the outflow tract (2) should
be convincingly demonstrated by imaging studies before it is
fully accepted as the mechanism for gradient reduction. A
reduction in the rate of ventricular emptying (dV/dT) through
an interruption of the sequence of contraction should be given
alternative consideration.
The long-term benefits and hazards of any new technology
should be judged against contemporary natural history studies.
The annual mortality rate is now reported to be ,1%, signifi-
cantly less than in earlier decades. As the cause or causes of
morbidity and mortality are better understood in hypertrophic
cardiomyopathy, rational and effective therapy has and will con-
tinue to emerge. Because arrhythmias and diastolic dysfunction
are now thought to be the principal causes of disability and death
in hypertrophic cardiomyopathy (with or without intracavitary
pressure gradients), will pacing confer benefit or hazard?
As with many conditions with familial association, future
therapy may be in the realm of genetic engineering. Many of
the arguments that dominate the discussions of hypertrophic
cardiomyopathy today may well be irrelevant if this prediction
is realized, but we can look back with nostalgia on these four
decades of intellectual stimulation. Myocardial stimulation
may be another matter.
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